Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response

Dedifferentiated chondrosarcomas (DDCS) are aggressive tumors with poor outcomes. Treatment of localized DDCS is primarily surgical, though most patients present with unresectable or metastatic disease. Systemic treatment options for advanced DDCS are limited, and the benefits of chemotherapy in this patient population remain controversial. Among other systemic therapy options, there is emerging clinical evidence to support the use of immunotherapy in patients with advanced DDCS. However, studies regarding the efficacy of immunotherapy in advanced DDCS are limited. Here, we present the case of a patient with metastatic, programmed death-ligand 1 (PD-L1)-positive DDCS treated with pembrolizumab who showed a sustained complete response for 24 months after initiation of therapy. To our knowledge, this case represents one of few documented cases of metastatic chondrosarcoma with sustained response to immunotherapy. The impressive response seen with PD-L1 inhibition in our patient indicates that immunotherapy is a successful treatment option in a subset of DDCS patients, and further investigation is needed to identify potential responders to immunotherapy.

[1]  G. Nielsen,et al.  Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution , 2019, Sarcoma.

[2]  B. Corinne,et al.  The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target , 2019, Journal of bone oncology.

[3]  S. Pollack,et al.  Response to PD1 inhibition in conventional chondrosarcoma , 2018, Journal of Immunotherapy for Cancer.

[4]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[5]  W. Yao,et al.  Dedifferentiated chondrosarcoma: Radiological features, prognostic factors and survival statistics in 23 patients , 2017, PloS one.

[6]  J. Blay,et al.  Description of the immune microenvironment of chondrosarcoma and contribution to progression , 2017, Oncoimmunology.

[7]  G. Rosen,et al.  Response to anti-PD1 therapy with nivolumab in metastatic sarcomas , 2016, Clinical Sarcoma Research.

[8]  X. Zang,et al.  Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma , 2016, Scientific Reports.

[9]  A. Italiano,et al.  Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype , 2016, Modern Pathology.

[10]  J. Schwab,et al.  The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma , 2015, Sarcoma.

[11]  Narasimhan P. Agaram,et al.  Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. , 2015, Human pathology.

[12]  K. Jang,et al.  Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas , 2013, PloS one.

[13]  K. Harimaya,et al.  Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute , 2012, Journal of Orthopaedic Surgery and Research.

[14]  L. Dodd,et al.  The Clinical Management of Chondrosarcoma , 2009, Current treatment options in oncology.

[15]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[16]  W. Fiedler,et al.  Dedifferentiated chondrosarcoma—a fatal disease , 2005, Journal of Cancer Research and Clinical Oncology.

[17]  F. Sim,et al.  Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. , 2004, The Journal of bone and joint surgery. American volume.

[18]  F. Sim,et al.  Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases. , 1986, The Journal of bone and joint surgery. American volume.

[19]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[20]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[21]  R. Grimer,et al.  Experience in the treatment of dedifferentiated chondrosarcoma. , 2000, The Journal of bone and joint surgery. British volume.